Agonista triple en investigación de los receptores de GIP/GLP-1/glucagón (LY3437943), de Eli Lilly, estudiado en ensayos de fase 3; no aprobado como medicamento en ningún lugar y no destinado al uso terapéutico en humanos.
Fase clínicaVial liofilizadoTambién conocido como:LY3437943 · Triple Receptor Agonist · Triple G
Aproximadamente 6 días (humano; Urva et al. 2022, fase 1b)
Almacenamiento
Polvo liofilizado por debajo de −15 °C, bien cerrado y protegido de la luz; dejar que el vial sellado alcance temperatura ambiente antes de abrirlo. Viales reconstituidos a 2–8 °C.
Tamaños
5 mg, 10 mg
Qué es
El compuesto. Origen, investigación y realidad regulatoria.
Retatrutide (development code LY3437943) is an investigational triple hormone-receptor agonist developed by Eli Lilly: a single synthetic peptide engineered to activate the GIP, GLP-1 and glucagon receptors. As of September 2026 it has not been approved as a medicine in any jurisdiction; Lilly states it is available only to participants in its clinical trials.
A Phase 1b multiple-ascending-dose study (Urva et al., 2022) characterised its pharmacokinetics, and a Phase 2 trial (Jastreboff et al., 2023) examined its triple-receptor mechanism and dose-dependent effect on body weight in adults with obesity. The Phase 3 TRIUMPH programme is evaluating retatrutide in obesity and related conditions.
The FDA states that retatrutide cannot be used in compounding under federal law and is not a component of any FDA-approved drug, and it has warned telehealth companies, distributors and outsourcing facilities that sold unapproved retatrutide falsely labelled ‘for research purposes’ or ‘not for human consumption’. Research-use-only vials sold commercially are outside Lilly’s clinical-trial supply chain and have not been reviewed for safety, effectiveness or quality.
Registro en vivo de proveedores · agrupado por dosis
Cada proveedor. Primero lo más barato por mg; los kits, aparte.
RETATRUTIDE · precio por mg
2 ofertaes · proveedores sin advertencia primero · Última actualización de los datos de ofertas: octubre de 2026
Mejor precio por mg: Pepsup 20 mg a 4,05 US$/mg.
10 mg
Ofertas: 1
01
Particle PeptidesVID-PARTICLE · Solo CL/UY · sold as 'GLP-3' · €121.94
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
It is not an approved medicine anywhere and the FDA states it cannot be used in compounding under federal law. Products sold research-use-only are for laboratory research, not human use; RUO labelling does not authorise personal use.
How is research-vial retatrutide different from a pharmacy product?
There is no approved pharmacy product to compare it with: retatrutide is investigational. Lilly states it is available only to its clinical-trial participants, so any vial sold commercially sits outside that controlled chain.
What should a CoA show for retatrutide?
HPLC purity, an LC-MS mass that matches the developer-published structure (vendor pages have been seen listing wrong CAS numbers and masses for this compound), a lot number, an independent third-party lab name and a test date.